CD123/CLL1 CAR-T Cell Therapy for Relapsed and Refractory Acute Myeloid Leukemia

Study Summary

The treatment options for relapse/refractory B-cell acute myeloid leukemia(AML)are limited.CD123/CLL1 CAR-T Cells may have a permanent anti-tumor effect and became very attractive. This study aims to assess the safety and toxicity of CD123/CLL1 CAR-T Cells to patients with relapse/refractory AML.

Interventions

Study Locations

Facility	City	State	Country
Fujian Medical University Union Hospital	Fuzhou	Fujian	China

Official Trial Information

View on ClinicalTrials.gov